The Heart in Inflammatory Myopathies

Rheumatic Disease Clinics of North America

Volumn 40, Issue 1, 2014, Pages 1-10

  Van Gelder, Howard ^a   Charles Schoeman, Christina ^b  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Dermatomyositis; Idiopathic inflammatory myopathies; Inclusion body myositis; Polymyositis

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; PREDNISONE; STEROID; SYNTHETASE; SYNTHETASE ATIBODY; TROPONIN I; UNCLASSIFIED DRUG;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DERMATOMYOSITIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROMYOGRAPHY; HEART ARREST; HEART ARRHYTHMIA; HEART DISEASE; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; JUVENILE DERMATOMYOSITIS; MORTALITY; MYOCARDITIS; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC DYSFUNCTION; VALVULAR HEART DISEASE;

CARDIOVASCULAR DISEASE; DERMATOMYOSITIS; IDIOPATHIC INFLAMMATORY MYOPATHIES; INCLUSION BODY MYOSITIS; POLYMYOSITIS;

CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; HEART; HUMANS; MYOSITIS; RISK FACTORS;

EID: 84888167632     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.10.002     Document Type: Review

References (30)

1. Nagaraju K., Lundberg I.E. Inflammatory diseases of muscle and other myopathies 2012, 1404-1430. Kelleys Textbook of Rheumatology. 9th edition.
2. National Institue of Environmental Health Sciences. International Myositis Assessment and Clinical Research (IMACS) 2011. Available at: http://www.niehs.nih.gov/news/events/pastmtg/imacs/index.cfm.
3. Cruellas M.G., Viana Vdos S., Levy-Neto M., et al. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in large series of patients with polymyositis and dermatomyositis. Clinics 2013, 68(7):909-914.
4. Wallace E., Wortmann R. Diagnosis and management of inflammatory muscle disease. JMusculoskelet Med 2001, 27:12.
5. Lundberg I.E. The heart in dermatomyositis and polymyositis. Rheumatology 2006, 45(Suppl 4):iv18-iv21.
6. Kassi M., Nabi F. Role of Cardiac MRI in the assessment of nonischemic cardiomyopahties. Methodist Debakey Cardiovasc J 2013, 9(3):149-155.
7. Mavrogeni S., Douskou M., Manoussakis M. Contrast-enhanced CMR imaging reveals myocardial involvement in idiopathic inflammatory myopathy without cardiac manifestations. JACC Cardiovasc Imaging 2011, 4:1324-1325.
8. Ponfick M., Gdynia H.J., Kassubek J., et al. Cardiac involvement in juvenile overlap-myositis detected by cardiac magnetic resonance imaging. Int J Cardiol 2011, 152:e25-e26.
9. Mavrogeni S., Bratis K., Karabela G., et al. Myocarditis during acute inflammatory myopathies-evaluations using clinical criteria and cardiac magnetic resonance imaging. Int J Cardiol 2013, 164:e3-e4.
10. Sénéchal M., Martin C., Poirier P. Myocardial dysfunction in polymyositis. Can J Cardiol 2006, 22(10):869-871.
11. Schwartz T., Sanner H., Husebye T., et al. Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 2011, 70:766-771.
12. Cox F., Delgado V., Vershuuren J., et al. The heart in sporadic inclusion body myositis: a study in 51 patients. JNeurol 2010, 257:447-451.
13. Ballo P., Chiodi L., Cameli M., et al. Dilated cardiomyopathy and inclusion body myositis. Neurol Sci 2012, 33:367-370.
14. Hollan I., Meroni P.L., Ahearn J.M., et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013, 12(10):1004-1015.
15. Linos E., Fiorentino D., Lingala B., et al. Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther 2013, 15:R7.
16. Zoller B., Li X., Sundquist J., et al. Risk of subsequent coronary heat disease in patients hospitalized for immune mediated diseases: a nationwide follow-up study from Sweden. PLoS One 2012, 7:e33442.
17. Zoller B., Li X., Sundquist J., et al. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow up study from Sweden. BMC Neurol 2012, 12:41.
18. Tisseverasinghe A., Bernatsky S., Pineau C.A. Arterial events in persons with Dermatomyositis and Polymyositis. JRheumatol 2009, 36(9):1943-1946.
19. Limaye V.S., Lester S., Blumbergs P., et al. Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus. Int J Rheum Dis 2010, 13:132-137.
20. Eimer M.J., Brickman W.J., Seashadri R., et al. Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyosits. JPediatr 2011, 159:795-801.
21. Soltész P., Dér H., Kerekes G., et al. Acomparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol 2009, 28:655-662.
22. Ceribelli A., Fredi M., Taraborelli M., et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012, 14(2):R97.
23. Gupta R., Siddharth A.W., Ira N.T., et al. Clinical cardiac involvement in idiopathic inflammatory myopathies: a systemic review. Int J Cardiol 2011, 148:261-270.
24. Zhang L., Wang G.C., Ma L., et al. Cardiac involvement in adult polymyositis or dermatomyositis: a systemic review. Clin Cardiol 2012, 35(11):686-691.
25. Shu X.M., Lu X., Xie Y., et al. Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China. BMC Neurol 2011, 11:143.
26. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21):2195-2207.
27. McCarey D.W., McInnes I.B., Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363(9426):2015-2021.
28. Mohassel P., Mammen A.L. The spectrum of statin myopathy. Curr Opin Rheumatol 2013, 25(6):747-752.
29. Mammen A.L., Chung T., Christopher-Stine L., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011, 63(3):713-721.
30. Charles-Schoeman C., Amjadi S.S., Paulus H.E. International Myositis and Clinical Studies Group. Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group Survey. Clin Rheumatol 2012, 3(8):1163-1168.